Cure Alveolar Soft Part Sarcoma International (iCureASPS)

Immunology. 2011 Mar; 132(3): 307–314.

doi: 10.1111/j.1365-2567.2010.03396.x


PMCID: PMC3044897

Tolerogenic dendritic cells and their potential applications

Jim Hu1,2 and Yonghong Wan3

Author information ► Article notes ► Copyright and License information ►


This article has been cited by other articles in PMC.

Abstract


Dendritic cells (DCs) play a pivotal role in regulating the balance between immunity and tolerance of the immune system. Recent advancements in DC biology and techniques for manipulating the function of these cells have shown their immense therapeutic potential for treating a variety of immune disorders. Theoretically, antigen-specific tolerogenic DCs can be generated in vitro and delivered to patients to correct the dysfunctional immune responses that attack their own tissues or over-react to innocuous foreign antigens. However, DCs are a heterogeneous population of cells with differences in cell surface makers, differentiation pathways and functions. Studies are needed to examine which subset of DCs can be used for what type of applications. Furthermore, most of the information on tolerogenic DCs has been obtained from animal models and translational studies are needed to examine how a DC therapeutic strategy can be implemented clinically to modulate immunity.

Keywords: dendritic cells, immune responses, T cells, therapy, tolerance

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3044897/

What Is Cancer Immunotherapy?

Cancer Immunotherapy

Impacting All Cancers

Sarcoma

Therapeutic Vaccines

Immunotherapies in Development Current experimental immunotherapies for sarcoma fall into three broad categories: adoptive T cell therapies, therapeutic cancer vaccines, and checkpoint inhibitors/immune modulators.


Therapeutic Vaccines

Therapeutic cancer vaccines are designed to elicit an immune response against tumor-specific or tumor-associated antigens, encouraging the immune system to attack cancer cells bearing these antigens.

A cancer vaccine composed of dendritic cells pulsed with overlapping peptides of NY-ESO1,MAGE-A1, and MAGE-A3 is in a phase I trial for the treatment of pediatric patients with relapsed high-risk Ewing sarcoma, osteogenic sarcoma, rhabdomyosarcoma, synovial sarcoma, and neuroblastoma (NCT01241162).

A dendritic cell vaccine is in a phase I trial for adults and children with sarcoma (soft tissue and bone) (NCT01803152)

FANG vaccine, which expresses an antigen and GM-CSF, is undergoing a phase I trial in Ewing sarcoma for children and adults (NCT01061840).


-

http://www.cancerresearch.org/cancer-im ... ll-cancers